Serum Bone Markers in Breast Cancer Patients During 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) Therapy
Background: Chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC) is now indicated for adjuvant therapy of breast cancer. Its effects on serum bone markers and bone metabolism are unclear. Patients and Methods: The bone formation marker serum osteocalcin, the bone resorption marker...
Gespeichert in:
| Veröffentlicht in: | Anticancer research 2004-03, Vol.24 (2C), p.1271-1274 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1274 |
|---|---|
| container_issue | 2C |
| container_start_page | 1271 |
| container_title | Anticancer research |
| container_volume | 24 |
| creator | KAILAJÄRVI, Marita E. H SALMINEN, Eeva K PAIJA, Outi M. M VIRTANEN, Arja M LEINO, Aila E IRJALA, Kerttu A |
| description | Background: Chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC) is now indicated for adjuvant therapy
of breast cancer. Its effects on serum bone markers and bone metabolism are unclear. Patients and Methods: The bone formation
marker serum osteocalcin, the bone resorption marker serum carboxyterminal telopeptide of type I collagen (CTx), serum parathyroid
hormone (PTH), 25-hydroxyvitamin D (25(OH)D) and calcium concentrations were assessed in nine premenopausal breast cancer
patients with no distant metastases at baseline, before the fourth cycle and after the ninth cycle of FEC therapy. All patients
became amenorrheic during chemotherapy. Results: Individual values of bone markers remained within the reference ranges. The
mean concentrations increased slightly. The only significant changes from baseline were observed in serum osteocalcin; concentrations
were 17.6±4.9 μg/l (mean±SD), 17.5±4.2 μg/l, 22.8±6.4 μg/l (p=0.003). Serum CTx concentrations were 998±605 pmol/l, 886±562
pmol/l and 1473±1102 pmol/l at baseline, before the 4th and after the 9th cycle (p=ns). Serum 25(OH)D concentrations were
all very low (mean concentrations were 26.6±10.1 mmol/l, 29.9±6.5 mmol/l and 27.7±10.6 mmol/l) and remained stable as did
mean serum PTH and calcium concentrations. Conclusion: The finding of slight increases of the bone markers suggests early
bone loss in premenopausal women. The independent effects of estrogen deprivation on bone cannot be separated from the effects
of FEC therapy on bone. |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_pasca</sourceid><recordid>TN_cdi_pubmed_primary_15154659</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>15154659</sourcerecordid><originalsourceid>FETCH-LOGICAL-h268t-a0e71ed6b52cf55950fa49dddc74de8edc8cc072f1a93416899ea85a6d8714ea3</originalsourceid><addsrcrecordid>eNpNz11LwzAYBeAgipvTvyC5URQsJG3TNJdaNxUmCs7r8i55u0b7ZdIi-_dWNsGrc_OcA-eATLlUPJAiYodkykLBAsmYmJAT7z8YSxKVRsdkwgUXcSLUlHy9oRtqetc2SJ_BfaLz1Db0ziH4nmbQaHT0FXqLTe_p_eBss6EiWFRD69rBgbbVDZ131g1rq8ciNIZmW121Xdn6roTaGqRXi3l2TVclOui2p-SogMrj2T5n5H0xX2WPwfLl4Sm7XQZlmKR9AAwlR5OsRagLIZRgBcTKGKNlbDBFo1OtmQwLDiqKeZIqhZAKSEwqeYwQzcj5brcb1jWavHO2BrfN_76P4GIPwGuoCjeetf6fk2qEv-5y50q7Kb-tw9zXUFXjbJSDC-M8zHIeSh79AN02cSw</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Serum Bone Markers in Breast Cancer Patients During 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) Therapy</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>KAILAJÄRVI, Marita E. H ; SALMINEN, Eeva K ; PAIJA, Outi M. M ; VIRTANEN, Arja M ; LEINO, Aila E ; IRJALA, Kerttu A</creator><creatorcontrib>KAILAJÄRVI, Marita E. H ; SALMINEN, Eeva K ; PAIJA, Outi M. M ; VIRTANEN, Arja M ; LEINO, Aila E ; IRJALA, Kerttu A</creatorcontrib><description>Background: Chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC) is now indicated for adjuvant therapy
of breast cancer. Its effects on serum bone markers and bone metabolism are unclear. Patients and Methods: The bone formation
marker serum osteocalcin, the bone resorption marker serum carboxyterminal telopeptide of type I collagen (CTx), serum parathyroid
hormone (PTH), 25-hydroxyvitamin D (25(OH)D) and calcium concentrations were assessed in nine premenopausal breast cancer
patients with no distant metastases at baseline, before the fourth cycle and after the ninth cycle of FEC therapy. All patients
became amenorrheic during chemotherapy. Results: Individual values of bone markers remained within the reference ranges. The
mean concentrations increased slightly. The only significant changes from baseline were observed in serum osteocalcin; concentrations
were 17.6±4.9 μg/l (mean±SD), 17.5±4.2 μg/l, 22.8±6.4 μg/l (p=0.003). Serum CTx concentrations were 998±605 pmol/l, 886±562
pmol/l and 1473±1102 pmol/l at baseline, before the 4th and after the 9th cycle (p=ns). Serum 25(OH)D concentrations were
all very low (mean concentrations were 26.6±10.1 mmol/l, 29.9±6.5 mmol/l and 27.7±10.6 mmol/l) and remained stable as did
mean serum PTH and calcium concentrations. Conclusion: The finding of slight increases of the bone markers suggests early
bone loss in premenopausal women. The independent effects of estrogen deprivation on bone cannot be separated from the effects
of FEC therapy on bone.</description><identifier>ISSN: 0250-7005</identifier><identifier>EISSN: 1791-7530</identifier><identifier>PMID: 15154659</identifier><language>eng</language><publisher>Attiki: International Institute of Anticancer Research</publisher><subject>Adult ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Bone and Bones - metabolism ; Bone Neoplasms - blood ; Bone Neoplasms - secretion ; Bone Resorption - blood ; Breast Neoplasms - blood ; Breast Neoplasms - drug therapy ; Breast Neoplasms - pathology ; Collagen - blood ; Collagen Type I ; Cyclophosphamide - administration & dosage ; Diseases of the osteoarticular system ; Epirubicin - administration & dosage ; Female ; Fluorouracil - administration & dosage ; Gynecology. Andrology. Obstetrics ; Humans ; Mammary gland diseases ; Medical sciences ; Middle Aged ; Neoplasm Staging ; Osteocalcin - blood ; Parathyroid Hormone - blood ; Peptides - blood ; Tumors ; Tumors of striated muscle and skeleton ; Vitamin D - analogs & derivatives ; Vitamin D - blood</subject><ispartof>Anticancer research, 2004-03, Vol.24 (2C), p.1271-1274</ispartof><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15795469$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15154659$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>KAILAJÄRVI, Marita E. H</creatorcontrib><creatorcontrib>SALMINEN, Eeva K</creatorcontrib><creatorcontrib>PAIJA, Outi M. M</creatorcontrib><creatorcontrib>VIRTANEN, Arja M</creatorcontrib><creatorcontrib>LEINO, Aila E</creatorcontrib><creatorcontrib>IRJALA, Kerttu A</creatorcontrib><title>Serum Bone Markers in Breast Cancer Patients During 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) Therapy</title><title>Anticancer research</title><addtitle>Anticancer Res</addtitle><description>Background: Chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC) is now indicated for adjuvant therapy
of breast cancer. Its effects on serum bone markers and bone metabolism are unclear. Patients and Methods: The bone formation
marker serum osteocalcin, the bone resorption marker serum carboxyterminal telopeptide of type I collagen (CTx), serum parathyroid
hormone (PTH), 25-hydroxyvitamin D (25(OH)D) and calcium concentrations were assessed in nine premenopausal breast cancer
patients with no distant metastases at baseline, before the fourth cycle and after the ninth cycle of FEC therapy. All patients
became amenorrheic during chemotherapy. Results: Individual values of bone markers remained within the reference ranges. The
mean concentrations increased slightly. The only significant changes from baseline were observed in serum osteocalcin; concentrations
were 17.6±4.9 μg/l (mean±SD), 17.5±4.2 μg/l, 22.8±6.4 μg/l (p=0.003). Serum CTx concentrations were 998±605 pmol/l, 886±562
pmol/l and 1473±1102 pmol/l at baseline, before the 4th and after the 9th cycle (p=ns). Serum 25(OH)D concentrations were
all very low (mean concentrations were 26.6±10.1 mmol/l, 29.9±6.5 mmol/l and 27.7±10.6 mmol/l) and remained stable as did
mean serum PTH and calcium concentrations. Conclusion: The finding of slight increases of the bone markers suggests early
bone loss in premenopausal women. The independent effects of estrogen deprivation on bone cannot be separated from the effects
of FEC therapy on bone.</description><subject>Adult</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Bone and Bones - metabolism</subject><subject>Bone Neoplasms - blood</subject><subject>Bone Neoplasms - secretion</subject><subject>Bone Resorption - blood</subject><subject>Breast Neoplasms - blood</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - pathology</subject><subject>Collagen - blood</subject><subject>Collagen Type I</subject><subject>Cyclophosphamide - administration & dosage</subject><subject>Diseases of the osteoarticular system</subject><subject>Epirubicin - administration & dosage</subject><subject>Female</subject><subject>Fluorouracil - administration & dosage</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Osteocalcin - blood</subject><subject>Parathyroid Hormone - blood</subject><subject>Peptides - blood</subject><subject>Tumors</subject><subject>Tumors of striated muscle and skeleton</subject><subject>Vitamin D - analogs & derivatives</subject><subject>Vitamin D - blood</subject><issn>0250-7005</issn><issn>1791-7530</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNz11LwzAYBeAgipvTvyC5URQsJG3TNJdaNxUmCs7r8i55u0b7ZdIi-_dWNsGrc_OcA-eATLlUPJAiYodkykLBAsmYmJAT7z8YSxKVRsdkwgUXcSLUlHy9oRtqetc2SJ_BfaLz1Db0ziH4nmbQaHT0FXqLTe_p_eBss6EiWFRD69rBgbbVDZ131g1rq8ciNIZmW121Xdn6roTaGqRXi3l2TVclOui2p-SogMrj2T5n5H0xX2WPwfLl4Sm7XQZlmKR9AAwlR5OsRagLIZRgBcTKGKNlbDBFo1OtmQwLDiqKeZIqhZAKSEwqeYwQzcj5brcb1jWavHO2BrfN_76P4GIPwGuoCjeetf6fk2qEv-5y50q7Kb-tw9zXUFXjbJSDC-M8zHIeSh79AN02cSw</recordid><startdate>20040301</startdate><enddate>20040301</enddate><creator>KAILAJÄRVI, Marita E. H</creator><creator>SALMINEN, Eeva K</creator><creator>PAIJA, Outi M. M</creator><creator>VIRTANEN, Arja M</creator><creator>LEINO, Aila E</creator><creator>IRJALA, Kerttu A</creator><general>International Institute of Anticancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>20040301</creationdate><title>Serum Bone Markers in Breast Cancer Patients During 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) Therapy</title><author>KAILAJÄRVI, Marita E. H ; SALMINEN, Eeva K ; PAIJA, Outi M. M ; VIRTANEN, Arja M ; LEINO, Aila E ; IRJALA, Kerttu A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h268t-a0e71ed6b52cf55950fa49dddc74de8edc8cc072f1a93416899ea85a6d8714ea3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adult</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Bone and Bones - metabolism</topic><topic>Bone Neoplasms - blood</topic><topic>Bone Neoplasms - secretion</topic><topic>Bone Resorption - blood</topic><topic>Breast Neoplasms - blood</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - pathology</topic><topic>Collagen - blood</topic><topic>Collagen Type I</topic><topic>Cyclophosphamide - administration & dosage</topic><topic>Diseases of the osteoarticular system</topic><topic>Epirubicin - administration & dosage</topic><topic>Female</topic><topic>Fluorouracil - administration & dosage</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Osteocalcin - blood</topic><topic>Parathyroid Hormone - blood</topic><topic>Peptides - blood</topic><topic>Tumors</topic><topic>Tumors of striated muscle and skeleton</topic><topic>Vitamin D - analogs & derivatives</topic><topic>Vitamin D - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>KAILAJÄRVI, Marita E. H</creatorcontrib><creatorcontrib>SALMINEN, Eeva K</creatorcontrib><creatorcontrib>PAIJA, Outi M. M</creatorcontrib><creatorcontrib>VIRTANEN, Arja M</creatorcontrib><creatorcontrib>LEINO, Aila E</creatorcontrib><creatorcontrib>IRJALA, Kerttu A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Anticancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>KAILAJÄRVI, Marita E. H</au><au>SALMINEN, Eeva K</au><au>PAIJA, Outi M. M</au><au>VIRTANEN, Arja M</au><au>LEINO, Aila E</au><au>IRJALA, Kerttu A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum Bone Markers in Breast Cancer Patients During 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) Therapy</atitle><jtitle>Anticancer research</jtitle><addtitle>Anticancer Res</addtitle><date>2004-03-01</date><risdate>2004</risdate><volume>24</volume><issue>2C</issue><spage>1271</spage><epage>1274</epage><pages>1271-1274</pages><issn>0250-7005</issn><eissn>1791-7530</eissn><abstract>Background: Chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC) is now indicated for adjuvant therapy
of breast cancer. Its effects on serum bone markers and bone metabolism are unclear. Patients and Methods: The bone formation
marker serum osteocalcin, the bone resorption marker serum carboxyterminal telopeptide of type I collagen (CTx), serum parathyroid
hormone (PTH), 25-hydroxyvitamin D (25(OH)D) and calcium concentrations were assessed in nine premenopausal breast cancer
patients with no distant metastases at baseline, before the fourth cycle and after the ninth cycle of FEC therapy. All patients
became amenorrheic during chemotherapy. Results: Individual values of bone markers remained within the reference ranges. The
mean concentrations increased slightly. The only significant changes from baseline were observed in serum osteocalcin; concentrations
were 17.6±4.9 μg/l (mean±SD), 17.5±4.2 μg/l, 22.8±6.4 μg/l (p=0.003). Serum CTx concentrations were 998±605 pmol/l, 886±562
pmol/l and 1473±1102 pmol/l at baseline, before the 4th and after the 9th cycle (p=ns). Serum 25(OH)D concentrations were
all very low (mean concentrations were 26.6±10.1 mmol/l, 29.9±6.5 mmol/l and 27.7±10.6 mmol/l) and remained stable as did
mean serum PTH and calcium concentrations. Conclusion: The finding of slight increases of the bone markers suggests early
bone loss in premenopausal women. The independent effects of estrogen deprivation on bone cannot be separated from the effects
of FEC therapy on bone.</abstract><cop>Attiki</cop><pub>International Institute of Anticancer Research</pub><pmid>15154659</pmid><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0250-7005 |
| ispartof | Anticancer research, 2004-03, Vol.24 (2C), p.1271-1274 |
| issn | 0250-7005 1791-7530 |
| language | eng |
| recordid | cdi_pubmed_primary_15154659 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adult Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Bone and Bones - metabolism Bone Neoplasms - blood Bone Neoplasms - secretion Bone Resorption - blood Breast Neoplasms - blood Breast Neoplasms - drug therapy Breast Neoplasms - pathology Collagen - blood Collagen Type I Cyclophosphamide - administration & dosage Diseases of the osteoarticular system Epirubicin - administration & dosage Female Fluorouracil - administration & dosage Gynecology. Andrology. Obstetrics Humans Mammary gland diseases Medical sciences Middle Aged Neoplasm Staging Osteocalcin - blood Parathyroid Hormone - blood Peptides - blood Tumors Tumors of striated muscle and skeleton Vitamin D - analogs & derivatives Vitamin D - blood |
| title | Serum Bone Markers in Breast Cancer Patients During 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) Therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T00%3A28%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20Bone%20Markers%20in%20Breast%20Cancer%20Patients%20During%205-Fluorouracil,%20Epirubicin%20and%20Cyclophosphamide%20(FEC)%20Therapy&rft.jtitle=Anticancer%20research&rft.au=KAILAJ%C3%84RVI,%20Marita%20E.%20H&rft.date=2004-03-01&rft.volume=24&rft.issue=2C&rft.spage=1271&rft.epage=1274&rft.pages=1271-1274&rft.issn=0250-7005&rft.eissn=1791-7530&rft_id=info:doi/&rft_dat=%3Cpubmed_pasca%3E15154659%3C/pubmed_pasca%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/15154659&rfr_iscdi=true |